Close Menu

stock downgrade

The investment bank said it expects that continued margin expansion will be more challenging than the company's stock price indicates.

The molecular diagnostics company said the number of Atlas instruments placed with customers under commercial agreements rose to 41 from 38 in Q4 2014.

The investment bank believes there's more risk for a downside on the company's stock than there is potential for an upside.

The investment bank said the company's stock has performed well in recent years and is now "appropriately priced."

The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.

Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.

GenMark officials announced an expected delay in launching the CE-marked version of the ePlex system, which in turn affected its US launch timeline.

The investment bank issued its downgrade citing concerns about changes to Cepheid's sales force and a flattening of its MRSA assay sales. 

In addition to a steep slide in the company's share price, Raymond James lowered its rating for Cepheid's stock to Market Perform.

BTIG and Mizuho downgraded Illumina's stock after it preannounced third quarter revenue estimates that fell short of analysts' average expectations.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.